Management and Scientific Team

Dr Nick Cerneaz joined Seeing Machines in 2005 to take responsibility for the commercialisation of the company’s glaucoma diagnostic technology. Nick brings to Seeing Machines significant industry experience developing and commercializing medical software and devices. Most recently Nick was the Chief Operations Officer and formerly Vice President of Engineering at Mirada Solutions Limited an Oxford UK based medical software company spun out from Oxford University in 1997. Nick was instrumental in building Mirada from its start-up origins through to a trade sale to CTI Molecular Imaging, which was itself acquired by Siemens Medical Systems, Inc in 2005.

Dr Sebastien Rougeaux, Principal Researcher B.Sc., GradDip Comp. Sci., M. Sc., Ph.D. Sebastien is a co-founder of Seeing Machines. He is an internationally known robotics and computer vision researcher with extensive experience in Japan and Australia. His research has been widely accepted as a landmark work in active computer vision. He is a significant contributor to building the Intellectual Property of Seeing Machines and is currently working full-time on the TrueField Analyzer project.

Dr Ted Maddess is a world-leading expert in vision research and the development of devices that aid diagnosis of eye diseases. At the Australian National University in the 1990s, Dr Maddess applied his knowledge of neurophysiology to glaucoma. He realized that the early stages of glaucoma, a common and irreversible form of blindness, could be detected using a special stimulus that appeals to nerve cells in the eye that measure luminance contrast. It took a decade of work to validate the concept, create a practical device, and turn his ideas into a successful medical instrument known as Frequency- Doubling-Technology Perimeter Device (or ‘‘FDT Perimeter’’). This device is now recognized, through 187 independent studies (ISI Index), as one of the best diagnostic instruments for mapping the visual field and is now sold globally through an alliance between Welch Allyn and Carl Zeiss Meditec.

In 2002 Dr Maddess received the prestigious Australian Academy of Technological Sciences and Engineering Clunies Ross Award for his contribution to science and technology. Prior to this he was also awarded the 1999 Australian Technology Prize for commercialization, and the 1990 Rimpac Prize for Innovative Research on glaucoma. Dr. Maddess holds a tenured research Readership (Senior Fellow) at the ANU’s prestigious Centre for Vision Research. Dr Maddess has prior experience in developing a glaucoma diagnostic device to the stage where it could be licensed to Welch Allyn and Carl Zeiss two of the most well known and successful names world wide in the medical devices business.

Dr Andrew JAMES Chief Investigator, ARC Centre of Excellence in Vision Science. Research Officer, Visual Sciences, RSBS, ANU.